AstraZeneca (AZN) says numbers published yesterday were based on a pre-specified interim analysis with a data cut-off of 17 February

March 23, 2021 7:53 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

(Updated - March 23, 2021 7:55 AM EDT)

AstraZeneca (NASDAQ: AZN) announced:

Update following statement by NIAID on AZD1222 US Phase III trial data

The numbers published yesterday were based on a pre-specified interim analysis with a data cut-off of 17 February.

We have reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis. We are now completing the validation of the statistical analysis.

We will immediately engage with the independent data safety monitoring board (DSMB) to share our primary analysis with the most up to date efficacy data. We intend to issue results of the primary analysis within 48 hours.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Hot FDA News